Format

Send to

Choose Destination
Clin J Oncol Nurs. 2018 Feb 1;22(1):E7-E17. doi: 10.1188/18.CJON.E7-E17.

Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation
.

Author information

1
St. James's Hospital in Dublin.
2
Westchester Medical Center.

Abstract

BACKGROUND:

Sinusoidal obstruction syndrome (SOS), also called hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) that affects about 1 in 7 patients undergoing this procedure. SOS/VOD is caused by the conditioning regimens administered prior to HSCT; in some cases, SOS/VOD results from chemotherapy alone. SOS/VOD usually develops within three weeks following HSCT; however, it can have later onset. 
.

OBJECTIVES:

Clearly understanding how SOS/VOD develops may support prompt detection and treatment when the condition arises.
.

METHODS:

Research on identification and management of SOS/VOD is summarized, and data from clinical trials are reviewed.
.

FINDINGS:

This article describes the syndrome, risk factors, signs and symptoms, and appropriate supportive care and treatment. The authors also offer some practical tips for detecting SOS/VOD and providing patient care, as well as the latest information on treating and preventing this condition.

KEYWORDS:

defibrotide; sinusoidal obstruction syndrome; veno-occlusive disease

PMID:
29350698
DOI:
10.1188/18.CJON.E7-E17
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Oncology Nursing Society
Loading ...
Support Center